Trials / Completed
CompletedNCT05974839
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 732 (actual)
- Sponsor
- State University of New York at Buffalo · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
Detailed description
To study the effect of ocrelizumab on cortical lesion accumulation in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, phase 3, placebo-controlled study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Ocrelizumab | Non-interventional |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
- First posted
- 2023-08-03
- Last updated
- 2024-09-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05974839. Inclusion in this directory is not an endorsement.